Biogen's monoclonal antibody felzartamab wins first global approval in China

RegulatoryapprovedfelzartamablenalidomidedexamethasonePositive

AI Analysis

Summary

Biogen's monoclonal antibody felzartamab received regulatory approval in China for second-line multiple myeloma treatment in combination with lenalidomide and dexamethasone, marking its first global approval.

Outcome Details

felzartamab approved in China for second-line multiple myeloma in combination with lenalidomide and dexamethasone

Importance:7/10

Sentiment:

0.80

regulatory approvalChinamonoclonal antibodymultiple myelomafirst global approval

Related Companies

$BIIB

Read the original article

Published by Endpoints News on August 14, 2026 5:11 PM

Read Original